Home \ Expert Opinion \ Mexidol® - how to apply?

Mexidol® - how to use?

Syndrome of attention deficit with hyperactivity as an interdisciplinary problem. Mexidol® children with ADHD

Age continuum of ischemic-hypoxic lesions of the brain. The use of Mexidol for ADHD in children and adults

Rehabilitation after Covid-19

Mexidol®. Rehabilitation after coronavirus

The effectiveness of Mexidol in a comorbid patient: with arterial hypertension, coronary heart disease, brain ischemia

Mexidol's effectiveness in a polymorbid patient

Features of conducting elderly patients in clinical practice

Mexidol®-Anti-Age (anti-aging) drug

Dorsopathy in general clinical practice

Mexidol® with degenerative diseases in the spine, neck pain, dizziness, brain ischemia

Announcement:

Mexidol® is an original drug, that is, an innovator in his international unauthorized name (MNN segment). It is the first time a synthesized active molecule, which has passed a full cycle of preclinical and clinical studies that proved the effectiveness of Mexidol . Mexidol is based on two related and functionally significant compounds: 2-ethyl-6-methyl-3-hydroxypyridine and succinate. The combination of these components determines the multimodal properties and a wide range of pharmacological effects of the drug Mexidol ® .

All video next video

Syndrome of attention deficit with hyperactivity as an interdisciplinary problem. Mexidol® children with ADHD

Age continuum of ischemic-hypoxic lesions of the brain. The use of Mexidol for ADHD in children and adults

Rehabilitation after Covid-19

Mexidol®. Rehabilitation after coronavirus

The effectiveness of Mexidol in a comorbid patient: with arterial hypertension, coronary heart disease, brain ischemia

Mexidol's effectiveness in a polymorbid patient

Features of conducting elderly patients in clinical practice

Mexidol®-Anti-Age (anti-aging) drug

Dorsopathy in general clinical practice

Mexidol® with degenerative diseases in the spine, neck pain, dizziness, brain ischemia

Block of articles on this topic

Original and reproduced drugs: what do the clinician need to know?

Author:
A.V. Schulkin, A.A. Filimonova
FSBEI in the Ryazan State Medical University of the Ministry of Health of Russia, Ryazan, Russia

To the question of the evidence base of neuroprotective therapy: Focus on ethylmethylhydroxypyridine succinate

Authors:
A.I. Kochetkov, N.A. Shatalova, M.V. Klepikova, T.V. Filippova, O.D. Ostroumova

FSBEA DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia, Moscow

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com